ArticleCancer diagnosis & prognosis
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Pneumocystis pneumonia (PCP) can be a life-threatening fungal infection for immunocompromised individuals. We report a case of PCP in a 75-year-old male with colorectal cancer receiving bevacizumab plus mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluorouracil) therapy. Case Report: The patient, diagnosed with unresectable advanced colorectal cancer, developed fever and neutropenia during the 40th course of bevacizumab plus mFOLFOX6 therapy and was diagnosed with febrile neutropenia. Moreover, laboratory tests and imaging studies indicated PCP. Although initial treatment with corticosteroids and trimethoprim-sulfamethoxazole temporarily improved the patient's condition, the patient later developed acute respiratory distress syndrome and succumbed to the disease. Lymphocytopenia associated with the prolonged bevacizumab plus mFOLFOX6 therapy may have contributed to the onset of PCP. Conclusion: This case reaffirms that advanced age, immunosuppression, and cumulative steroid exposure are critical risk factors for PCP. Early imaging and prophylactic TMP-SMX administration should be considered in high-risk patients. Early intervention is crucial to prevent PCP progression to ARDS in patients with solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.